The next generation of AG1 is clinically backed.
RESEARCH STUDIES

AG1 is backed by clinical research

Our innovation is powered by continuous investment in scientific research and clinical discovery. We make sure the benefits of our product are thoroughly studied, and all claims are backed by a strong body of evidence – from ingredient-level research to clinical trials on the finished formula.
The result? AG1 doesn’t just feel different – the impact is measurable.

One product, four gold-standard clinical trials.

AG1 has undergone multiple gold-standard clinical trials – repeatedly proving its effectiveness in supporting nutrient absorption across different populations and study designs.

Tested for impact on:

One product, four gold-standard clinical trials.

AG1 has undergone multiple gold-standard clinical trials – repeatedly proving its effectiveness in supporting nutrient absorption across different populations and study designs.

Tested for impact on:

Our research findings

NUTRIENT LEVELS

AG1 helps improve key nutrient levels within 3 months.ᵃ

AG1 decreases Homocystein levels.ᵃ

WHY THIS MATTERS
Homocysteine ​​is an indicator of sufficient supply of B vitamins. A low-normal homocysteine level suggests a good B6, B12, and folate status - nutrients that among others support the homocystein metabolism. A functioning homocysteine ​​metabolism prevents the accumulation of intracellular homocysteine ​​and subsequent export into the blood, where it can contribute to oxidative stress.

AG1 increases Vitamin C levelsᵃ

WHY THIS MATTERS
Representing antioxidants in AG1, Vitamin C plays an important role in defending the body against oxidative stress³ and supporting immune function¹. As a powerful antioxidant, it’s essential to a wide range of physiological, psychological and cellular functions¹,²،⁴.
MICROBIOME

AG1 is clinically shown to enrich the gut microbiome.ᵃ⁻ᶜ

Over 10x average increase in friendly bacteria in the gut.ᵃ⁻ᶜ

WHY THIS MATTERS
These good bacteria live in the gut as part of a healthy microbiome.
BIOAVILABILITY

Key nutrients in AG1 were shown to be quickly and easily absorbed into the body.ᵈ

Thiamine levels were significantly increased within 30 minutes of drinking AG1.ᵈ

WHY THIS MATTERS
AG1 delivers key nutrients like thiamine, biotin, riboflavin, niacin, vitamin C, zinc and folate – in bioavailable forms the body can easily and readily utilize, maximizing their potential benefits.

a. In a triple-blind, randomised, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
b. In a double-blind, randomised, placebo-controlled 2-week cross-over clinical trial assessing microbiome shifts in 20 active adults ages 19-37.
c. In a double-blind, randomised, placebo-controlled 2-week cross-over clinical trial assessing microbiome shifts of 24 healthy adults with occasional GI distress ages 26-59.
d. In a double-blind, randomised, placebo-controlled cross-over clinical trial assessing bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.
The studies were conducted on a similar version of AG1's continually evolving formulation. The transferability of the study results is ensured because of comparable ingredients and amounts.

What powers our research

There are many ways to study how nutrition affects the body. In our clinical research, we use advanced tools and technologies – together with our academic and clinical partners – to explore the connection between nutrient intake and microbiome composition.

Our Team

Our research team

Our in-house team of clinicians and scientists bring diverse expertise across nutrition, metabolism, microbiome, and related fields. We also collaborate with independent experts, academic institutions, and clinical partners to advance research and expand our understanding with cutting-edge technology.

The clinical research lifecycle

We’re proud to share that four clinical trials – rigorously designed, randomised, placebo-controlled trials – on the AG1 formula have been completed. This is a major milestone in our scientific journey and one that underscores our long-standing commitment to evidence-based innovation.

Just like the trials themselves, the clinical research lifecycle is also rigorous, and it can be lengthy.

The process of undertaking a trial, analysing the results, and publishing them can take years. But we know it’s worth the wait, because we’re committed to advancing science – not just for the sake of innovation, but to contribute meaningfully to advancing the science of nutrition and the microbiome forward.

How the trials were conducted

  • AG1’s diverse team of clinicians, researchers, and PhDs work together to build initial studies.
  • The team conducted pre-clinical trials to inform the clinical trials. Pre-clinical studies were intentionally conducted to better understand the biological activity and mechanisms of AG1 – an approach that’s both common and foundational in the development of nutrition research. These early insights help inform the design of human clinical trials, enhancing scientific rigour and ensuring that future studies are strategically and effectively guided. Pre-clinical trials can take upwards of 8–10 months to design, implement and analyse the results.
  • We then partnered with independent contract research organisations (CROs) – the same groups trusted by other companies and academic institutions – to ensure data collection and analysis were objective and professionally managed.
  • To ensure scientific integrity and ethical compliance, each human study protocol was submitted for review and approval by an independent Institutional Review Board (IRB) prior to participant recruitment. IRB approval is a critical regulatory step that ensures the rights, safety, and well-being of study participants are protected, and that the research is conducted according to Good Clinical Practice (GCP) and applicable regulations. No human study began without formal IRB approval.
  • We then created detailed protocols with third-party scientists (also known as principal scientists) outlining specific criteria including the study population, endpoints, duration, measurements, and statistical plan. The research partners then recruited participants to ensure the most objective outcome for each study design. Participants and the third-party researchers in the trials were “blinded,” meaning they did not know they were taking AG1 or a placebo. As part of the design, our scientists and statisticians helped determine the power of the study – which refers to the likelihood that the study would detect a true effect if one existed, ensuring the results would be scientifically meaningful and not due to chance.
  • Each study was conducted over varying lengths of time, designed specifically to help answer the research questions – whether AG1 could measurably impact specific markers such as nutrient status, or microbiome composition in various populations from healthy individuals, active people to those with occasional gut issues.

After the trials were completed

What happens next

Peer-reviewed research

At AG1, science is at the heart of everything we do. Our commitment to research goes beyond any single formulation – we invest in rigorous, ongoing clinical studies to explore the role of foundational nutrition in overall health.

Beyond sharing our findings, we work with leading researchers to submit study manuscripts to peer-reviewed scientific journals – contributing to the broader scientific dialogue on the vital role of nutrition and the microbiome in overall health. To date, our peer-reviewed publications include both literature reviews and research on the AG1 original formula, which you can explore here.

In addition, multiple clinical studies on AG1 have been completed, and several abstracts have been accepted at upcoming national scientific conferences. As they are presented and published, we will update this page. In parallel, we are also working on several manuscripts which will be submitted to peer reviewed journals and published here upon acceptance.

JOURNAL OF THE INTERNATIONAL SOCIETY OF SPORTS NUTRITION

The effects of AG1® supplementation on the gut microbiome of healthy adults: a randomized, double-blind, placebo-controlled clinical trial

This study investigated the effects of AG1® supplementation on the gut microbiome, GI tolerability, and clinical safety markers in healthy adults. After four weeks, AG1® enriched beneficial probiotic taxa, showed a potential improvement in digestive quality of life, and did not negatively impact stool consistency, bowel frequency, or clinical safety markers, demonstrating its safety for daily use.

Read paper
NUTRIENTS

Foundational Nutrition: Implications for Human Health

Human nutrition, and what can be considered “ideal” nutrition, is a complex, multi-faceted topic which many researchers and practitioners deliberate. While some attest that basic human nutrition is relatively understood, it is undeniable that a global nutritional problem persists.

Read paper
FRONTIERS

Nutrient synergy: definition, evidence, and future directions

Nutrient synergy refers to the concept that the combined effects of two or more nutrients working together have a greater physiological impact on the body than when each nutrient is consumed individually.

Read paper
NUTRACEUTICALS

The Novel Synbiotic, AG1®, Increases Short-Chained Fatty Acid Production in the Simulator of Human Intestinal Microbial Ecosystem (SHIME) Model®

Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.

Read paper
APPLIED BIOSCIENCE

AG1®, a Novel Synbiotic, Demonstrates Superior Mineral Bioaccessibility and Bioavailability Compared to a Tablet Multivitamin and Mineral Supplement Using an In Vitro Model of the Upper Gastrointestinal Tract

While traditional multivitamin and mineral (MVM) supplements generally come in tablet form, new powder forms of MVM supplements are available with theoretically higher bioavailability relative to tablet MVM supplements. which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.

Read paper
CURRENT ISSUES IN MOLECULAR BIOLOGY

AG1® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the Simulator of Human Intestinal Microbial Ecosystem® Model

The study using the SHIME® model demonstrated that AG1® had a significant impact on the composition of the human gut microbiota, leading to differential enrichment of bacterial taxa and metabolic pathways, suggesting potential favorable effects on gut microbial composition following AG1® supplementation. Kirby et al 2024.

Read paper
MICROORGANISMS

AG1®, a Novel Synbiotic, Maintains Gut Barrier Function following Inflammatory Challenge in a Caco-2/THP1-Blue™ Co-Culture Model

This in vitro study assessed the impact of AG1, a synbiotic supplement, on gastrointestinal (GI) permeability following an inflammatory challenge. Using a human GI tract model, AG1 was found to significantly improve transepithelial electrical resistance (TEER), suggesting protective effects on GI permeability compared to a control. No significant differences in inflammatory markers were observed, and the beneficial effects may be driven by short-chain fatty acid (SCFA) production from AG1’s prebiotic and probiotic components.

Read paper
JOURNAL OF FUNCTIONAL FOODS

Changes in the fecal polar metabolome due to AG1 supplementation in the SHIME® model: A proof of principle study

Metabolomics is a critical approach to fully understand the metabolic repercussions of a nutritional supplement on the gut microbiota. Here, a proof of principle study was conducted via a metabolomic survey of polar metabolites to explore the effect of AG1 on the metabolic output of the human gut microbiota, in vitro, using the Simulator of the Human Intestinal Microbial Ecosystem® (SHIME)

Read paper

FAQs

What studies have been done on AG1?

AG1 has been studied across multiple clinical trials, consistently demonstrating its effectiveness in increasing nutrient levels and enriching the microbiome.

  • Triple-blind, randomised, placebo-controlled trial (105 healthy adults who consumed a Standard American Diet) measuring nutrient biomarkers and microbiome changes.
  • Double-blind, placebo-controlled crossover trial (20 highly active healthy adults) assessing microbiome changes.
  • Double-blind, placebo-controlled crossover trial (24 healthy adults with occasional digestive discomfort) assessing microbiome changes.
  • Double-blind, placebo-controlled crossover trial (16 healthy adults) measuring nutrient absorption and bioavailability.

What did the studies find?

What is a “gold standard” clinical trial?

Is this research published in peer-reviewed journals?

What measures do you take to ensure the quality of AG1?